



30th
Anniversary



2025 ANNUAL MEETING

The Boca Raton
Boca Raton, Florida
November 12–15

THANK YOU

The Connective Tissue Oncology Society
greatly appreciates your support of the 2025 Annual Meeting.

PLATINUM SPONSORS



Daiichi-Sankyo



GOLD SPONSOR



SILVER SPONSORS



BRONZE SPONSORS





Welcome to the 30th Anniversary of CTOS!

We are delighted to present the CTOS Annual Meeting in beautiful Boca Raton, the birthplace of CTOS. This year, we are celebrating 30 years of this important milestone by reflecting on how much our society has grown over the decades, becoming a thriving global community.

The program will begin by recounting the history of CTOS, celebrating its legacy while maximizing the value of the research findings shared in your abstracts. By fostering collaboration, we aim to continuously advance our understanding of sarcoma biology and improve patient care, all while remaining open to the future and embracing innovation.

Other highlights of the program will be the Herman Suit Lecturer, Dr. Paolo dei Tos, and the Nina Axelrad Lecturer, Dr. Carol Swallow. The Sarcoma of the Year will be Chondrosarcoma, a challenging disease to treat, where multidisciplinary collaboration is essential. Excitingly, new therapies are finally in development, making it an especially compelling topic for us to discuss together.

On Wednesday prior to the start of the meeting, there will once again be The Foundations of Sarcoma Science Symposium, as well as TARPSWG, Ultra-Rare Sarcomas, and SARC meetings. All registrants are welcome to attend these meetings.

As always, networking is a key highlight of CTOS. Attendees will have ample opportunities to connect with colleagues during receptions, breakfast, lunches, and at our spectacular 30th Anniversary Gala on Friday night! In addition, this year we're excited to introduce morning Volleyball competitions among the specialties to help kickstart the day. It's going to be a dynamic and engaging experience for all!

See you in Boca Raton!

Sincerely yours,
Silvia Stacchiotti, MD, 2025 CTOS President

2025 Program Committee
Dario Callegaro, MD
Liz Connolly, MbChB
Gina D'Amato, MD
Aisha Miah MBBS, PhD
Jason Sicklick, MD

IN TGCT

GO BEYOND TUMOR RESPONSE

WITH PROVEN SYMPTOMATIC
AND FUNCTIONAL IMPROVEMENTS^{2*}

In adults with symptomatic TGCT when surgery will potentially cause worsening functional limitation or severe morbidity²

See the tumor response data, active ROM results, impact on PROs like physical function and worst pain, and safety profile at [ROMVIMZAHCP.com](https://romvimzahcp.com)

*Improved function is defined as an improvement in PROMIS-PF, which measures a patient's ability to do a range of daily activities.^{3,4}

NCCN=National Comprehensive Cancer Network® (NCCN®); PRO=patient-reported outcome; PROMIS-PF=Patient-Reported Outcomes Measurement Information System Physical Function (TGCT-specific); ROM=range of motion; TGCT=tenosynovial giant cell tumor.

INDICATIONS AND USAGE

ROMVIMZA is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hepatotoxicity:

- Cases of serious and fatal liver injury have occurred with the use of another kinase inhibitor that targets CSF1R. Serious and fatal liver injury have not been observed with ROMVIMZA.
- Elevated AST and ALT can occur with ROMVIMZA.
- Avoid ROMVIMZA in patients with pre-existing increased serum transaminases; total bilirubin or direct bilirubin (>ULN); or active liver or biliary tract disease, including ALP.
- Monitor liver function tests prior to initiation of ROMVIMZA, twice a month for the first two months and once every 3 months for the first year of therapy and as clinically indicated thereafter. Withhold and reduce the dose, or permanently discontinue ROMVIMZA based on the severity of the hepatotoxicity.

Embryo-Fetal Toxicity:

- ROMVIMZA may cause fetal harm when administered to pregnant women. Advise pregnant women on the potential risk to the fetus.
- Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with ROMVIMZA and for 1 month after the last dose.

Allergic Reactions to FD&C Yellow No. 5 (Tartrazine) and No. 6 (Sunset Yellow FCF):

- ROMVIMZA 20 mg capsule contains FD&C Yellow No. 5 (tartrazine) which may cause allergic reactions (including bronchial asthma) in certain susceptible patients. FD&C Yellow No. 5 (tartrazine) sensitivity is frequently seen in patients who also have aspirin sensitivity.

- Advise patients that ROMVIMZA 14 mg and 20 mg capsules contain FD&C Yellow No. 6 (Sunset Yellow FCF), which may cause allergic reactions.

Increased Creatinine without Affecting Renal Function:

- Increases in serum creatinine can occur with the use of ROMVIMZA. These increases in serum creatinine may not be associated with changes in renal function. Increases in creatinine reversed upon ROMVIMZA discontinuation. During ROMVIMZA treatment, use alternative measures that are not based on serum creatinine to assess renal function.

Adverse Reactions:

The most common (≥20%) adverse reactions, including laboratory abnormalities that occurred in patients receiving ROMVIMZA were increased AST, periorbital edema, fatigue, rash, increased cholesterol, peripheral edema, face edema, decreased neutrophils, decreased leukocytes, pruritus, and increased ALT.

Drug Interactions:

- **P-glycoprotein (P-gp) substrates:** Avoid concomitant use of ROMVIMZA with P-gp substrates. If concomitant use cannot be avoided, take ROMVIMZA at least 4 hours prior to P-gp substrates.
- **Breast Cancer Resistance Protein (BCRP) substrates:** Avoid concomitant use of ROMVIMZA with BCRP substrates.
- **Organic Cation Transporter 2 (OCT2) substrates:** Avoid concomitant use of ROMVIMZA with OCT2 substrates.
- Concomitant use of vimseltinib with P-gp substrates, BCRP substrates or OCT2 substrates may increase exposure of these substrates.

Lactation: Advise females not to breastfeed during treatment with ROMVIMZA.

Please click for the full Prescribing Information.

References: **1.** Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.5.2024. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed March 12, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. **2.** ROMVIMZA [package insert]. Waltham, MA: Deciphera Pharmaceuticals, LLC. **3.** Gelderblom H, Bhadri V, Stacchiotti S, et al. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2024;403(10445):2709-2719. **4.** Gelderblom H, Bhadri V, Stacchiotti S, et al. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2024;403(10445)(suppl):1-124.





30th
Anniversary

2025 BOARD OF DIRECTORS

Silvia Stacchiotti, MD, President

Robin Jones, MD, Vice President

Maureen O'Sullivan, MD, Secretary

Abha Gupta, MD, Treasurer

Damon Reed, MD, Immediate Past President

Sandra D'Angelo, MD (2023-2025)

Rebecca Gladdy, MD, PhD (2023-2025)

Nadia Hindi, MD (2023-2025)

Torsten Nielsen, MD, PhD (2023-2025)

Ashleigh Guadagnolo, MD (2024-2026)

Sebastian Bauer, MD (2024-2026)

Paul Huang, MD (2024-2026)

Ana Sebio, MD, PhD (2025-2027)

Jason Sicklick, MD, FACS (2025-2027)

Odion Binitie, MD, PhD (2025-2027)

Tom Chen, MD (2025-2027)

Barbara Rapp, Executive Director





SpringWorks®
THERAPEUTICS

EMD
SERONO

Healthcare Companies of
Merck KGaA, Darmstadt, Germany

WELCOME TO
CTOS
2025

WE'RE WORKING TO
REIMAGINE
THE FUTURE OF TGCT CARE.

TGCT=tenosynovial giant cell tumor
©2025 Merck KGaA, Darmstadt, Germany or its affiliates.
All rights reserved. US-NONOTGCT-00021 10/25



Follow SpringWorks Therapeutics
& EMD Serono on LinkedIn



30th
Anniversary

2025 ANNUAL MEETING

at The Boca Raton • Boca Raton, Florida

November 12 – 15, 2025

SCHEDULE AT A GLANCE

WEDNESDAY, NOVEMBER 12, 2025

6:30 AM – 5:30 PM	Registration	Royal Palm Foyer
6:45 AM – 7:45 AM	CTOS Volleyball	Grand Lawn
7:00 AM – 8:00 AM	Breakfast	Royal Assembly, Addison Assembly
8:00 AM – 12:00 PM	TARPSWG	Addison Ballroom
8:00 AM – 3:00 PM	Foundational Science of Sarcomas Symposium Chairs: Jason Sicklick, MD, FACS Torsten O. Nielsen MD, PhD FRCPC	Royal Palm Ballroom
12:00 PM – 5:30 PM	Poster Set-Up	Grand Ballroom
1:00 PM – 3:00 PM	Ultra-Rare Sarcoma Meeting	Addison Ballroom
3:30 PM – 5:30 PM	SARC Meeting	Royal Palm Ballroom
5:30 PM – 7:00 PM	CTOS WELCOME RECEPTION	Grand Lawn
6:30 PM – 8:30 PM	See Sponsored Events on the CTOS Meeting Website	

SERVIER 
moved by you



Ogsiveo[®]
(nirogacestat)
150 mg & 100 mg tablets

Discover the **first and only**
FDA-approved therapy of its kind

Learn more at ogsiveo.com/hcp



THURSDAY, NOVEMBER 13, 2025

6:30 AM – 5:30 PM	Registration	Royal Palm Foyer
7:00 AM – 8:00 AM	Sunrise Mentorship, Breakfast and Posters	Grand Ballroom
8:00 AM – 9:30 AM	OPENING SESSION and CELEBRATION OF CTOS³ctos	Royal Palm Ballroom
8:30 AM – 5:00 PM	SPAGN Patient Advocacy Lounge	Estate II & III
9:00 AM – 5:30 PM	Nursing and Allied Health Meeting	Addison East
9:30 AM – 10:00 AM	HERMAN SUIT LECTURE The Evolution of Sarcoma Classification: An Unexpected Journey Lecturer: <i>Dr. Paolo Dei Tos</i>	Royal Palm Ballroom
10:00 AM – 10:30 AM	Coffee Break and Posters	Grand Ballroom
10:30 AM – 11:30 AM	SESSION 1: Pediatric & AYA Sarcomas: Treatment, Risk and Survivorship Moderators: <i>Najat C. Daw, MD; David Thomas, FRACP, PhD;</i> <i>Safia K. Ahmed, MD</i>	Royal Palm Ballroom
11:30 AM – 12:30 PM	SESSION 2: Novel Targets and Smart Drug Delivery Moderators: <i>Alessandra Merlini, MD PhD;</i> <i>David S. Shulman, MD; Sandra P. D'Angelo, MD</i>	Royal Palm Ballroom
12:30 PM – 1:30 PM	Lunch	Grand Ballroom
12:30 PM – 1:30 PM	Executive Committee Meeting	Estate I



Discovering new precision medicines in oncology

Scan the QR code for more information on Cogent and our clinical trials in GIST and oncology



TURALIO is honored to continue SUPPORTING CTOS AT THE 2025 ANNUAL MEETING.

**Join us at our onsite office, Mizner Wing Room, to
learn more about TURALIO at CTOS.**



Visit **TURALIOHCP.COM** to learn more.

Please see Full Prescribing Information, including **Boxed WARNING (Hepatotoxicity)**, and Medication Guide. TURALIO is only available through a REMS program.


THURSDAY, NOVEMBER 13, 2025, CONTINUED

1:30 PM – 3:00 PM	SESSION 3: Immunotherapy and Cell Therapy in Sarcoma: Emerging Frontiers Moderators: <i>Antoine Italiano, MD, PhD; John E. Mullinax, MD; Everett J. Moding, MD, PhD</i>	<i>Royal Palm Ballroom</i>
3:00 PM – 3:45 PM	DEBATE #1: The Great Debate: How Far Should We Go Before the Knife? Balancing RTx, CTx and IO in High-Risk UPS of the Extremities Moderator: <i>Alessandro Gronchi, MD</i> Presenters: <i>Ashley Drohan David E. Gyorki, MBBS, MD, FRACS Lorenzo D'Ambrosio, MD, PhD Everett J. Moding, MD, PhD</i>	<i>Royal Palm Ballroom</i>
3:45 PM – 4:15 PM	Coffee Break and Posters	<i>Grand Ballroom</i>
4:15 PM – 5:30 PM	SESSION 4: Sarcoma Biology and Therapeutic Implications Moderators: <i>Candace L. Haddox, MD; David S. Da Silva Moura, MD, PhD; Pawel Sobczuk, MD, PhD</i>	<i>Royal Palm Ballroom</i>
5:30 PM – 6:30 PM	POSTER RECEPTION	<i>Grand Ballroom</i>
6:30 PM	<u>See Sponsored Events on the CTOS Meeting Website</u>	

The logo for Parabillis Medicines features the word "Parabillis" in a large, dark grey, sans-serif font. Below it, the word "MEDICINES" is written in a smaller, all-caps, dark grey, sans-serif font. To the left of the text, there are several thick, curved, orange and red lines that sweep upwards and to the right, resembling stylized orbits or a parabolic path.

Parabillis
MEDICINES





DIVE INTO THE DATA



LEARN MORE AT
FYARROHCP.COM

FYARRO is only approved in the U.S.
Intended for U.S.-based healthcare professionals.



FYARRO® is a trademark of Aadi Bioscience, Inc.
© 2025 Aadi Bioscience, Inc. All rights reserved. US-FYA-2500030 10/25


FRIDAY, NOVEMBER 14, 2025

6:30 AM – 6:00 PM	Registration	Royal Palm Foyer
6:45 AM – 7:45 AM	CTOS Volleyball	Grand Lawn
7:00 AM – 8:30 AM	Breakfast	Grand Ballroom
8:30 AM – 10:00 AM	SESSION 5: SARCOMA OF THE YEAR: Chondrosarcoma Moderators: <i>Shreyaskumar Patel, MD; Judith V.M.G Bovee, MD, PhD; Jay S. Wunder, MD, MSc, FRCSC; Jeffrey Kramer, MS</i>	Royal Palm Ballroom
8:30 AM – 5:00 PM	SPAGN Patient Advocacy Lounge	Estate II & III
10:00 AM – 10:30 AM	Coffee Break and Posters	Grand Ballroom
10:30 AM – 12:00 PM	SESSION 6: Ultra-Rare Sarcomas: Opportunities from Molecular Insights Moderators: <i>Anna Maria Frezza, MD; Fiona Maclean, PhD; Josh Sommer</i>	Royal Palm Ballroom
12:00 PM – 12:30 PM	NINA AXELRAD LECTURE More Than a Blade: Confessions of a Sarcoma Surgeon Lecturer: <i>Dr. Carol Swallow</i>	Royal Palm Ballroom
12:30 PM – 1:30 PM	Lunch	Grand Ballroom
12:30 PM – 1:30 PM	Board of Directors Meeting	Estate I
12:30 PM – 1:30 PM	Young Investigator Lunch	Addison Ballroom

 **natera™** | **ONCOLOGY**

Signatera™ for sarcoma

Personalized, tumor-informed ctDNA molecular residual disease (MRD) testing to inform sarcoma patient care across all subtypes



ctDNA may aid in detecting minimal residual disease or recurrence in sarcomas¹

Signatera™ MRD testing detected sarcoma recurrence with 89% sensitivity and 100% specificity across >15 subtypes¹

Largest cohort of bone or soft tissue sarcoma patients retrospectively analyzed using a tumor-informed ctDNA assay to date



Discover more at
natera.com/oncology

References: 1. Sun, B, Yue, T, Hur, D, et al. Using Circulating Tumor DNA to Monitor Sarcoma Treatment and Recurrence. Oral Presentation at SSO, Tampa, FL, March 27-29, 2025
Signatera™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2025 Natera, Inc. All Rights Reserved. 20251017_NAT-8023127





Getting ahead of cancer together



© 2025 GSK group of companies or its licensor. All rights reserved.
NX-GBL-ON-ADVR-250011 | October 2025.

FRIDAY, NOVEMBER 14, 2025, CONTINUED

1:30 PM – 2:30 PM	SESSION 7: Retroperitoneal Sarcoma: Surgery, Biology and Beyond Moderators: <i>Fahima Dossa, MD, PhD; David Konieczkowski, MD, PhD; Juliana Restrepo, MD, MSc</i>	<i>Royal Palm Ballroom</i>
2:30 PM – 3:30 PM	SESSION 8: TGCT & Desmoid Tumor Moderators: <i>Rashmi Chugh, MD; Mrinal M. Gounder, MD; Sylvie Bonvalot, MD</i>	<i>Royal Palm Ballroom</i>
3:30 PM – 4:00 PM	Coffee Break and Posters	<i>Grand Ballroom</i>
4:00 PM – 5:00 PM	SESSION 9: Sarcoma and Society: Quality of Life and Global Care Moderators: <i>Catherine Sarre, MD; Roberto Pestana, MD, PhD; Winette T.A. T. van der Graaf, MD, PhD</i>	<i>Royal Palm Ballroom</i>
5:00 PM – 6:00 PM	SESSION 10: Pediatric and Adult Rhabdomyosarcoma: Biology to Bedside Moderators: <i>Herbert H. Loong, MBBS, PDipMDPath, MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine); David J. Papke, Jr, MD, PhD; Aditi Dhir, MD</i>	<i>Royal Palm Ballroom</i>
7:00 PM – 10:00 PM	Gala	<i>Harborside Pool Area</i>



10:00 PM – 1:00 AM	Gala After Party	<i>Cathedral, Cloister Building</i>
--------------------	-------------------------	-------------------------------------



Learn about the results of the ChonDRAgon clinical trial

ChonDRAgon is a randomized registrational phase 2 study of ozekibart (INBRX-109) in unresectable or metastatic conventional chondrosarcoma



Scan or [click here](#) to find out more

Ozekibart (INBRX-109) is an investigational medicine whose efficacy and safety profile have not been established. It has not been approved by the U.S. FDA or other health authority for any use.

INHIBRX

SATURDAY, NOVEMBER 15, 2025

7:00 AM – 5:00 PM	Registration	Royal Palm Foyer
7:00 AM – 9:00 AM	Breakfast	Grand Ballroom
7:30 AM – 8:30 AM	CTOS Volleyball	Grand Lawn
8:30 AM – 5:00 PM	SPAGN Patient Advocacy Lounge	Estate II & III
9:00 AM – 10:30 AM	SESSION 11: AI and Omics for Prognostication and Precision Medicine Moderators: <i>Lorenzo D'Ambrosio, MD PhD;</i> <i>Elizabeth J. Lilley, MD, MPH; Armelle Dufresne, MD PhD</i>	Royal Palm Ballroom
10:30 AM – 11:00 AM	Coffee Break and Posters	Grand Ballroom
11:00 AM – 12:00 PM	SESSION 12: Radiotherapy in Sarcoma Moderators: <i>Ninna Aggerholm-Pedersen, Associate Professor, PhD, MD;</i> <i>William D. Tap, MD; Miranda Lam, MD, MBA</i>	Royal Palm Ballroom
12:00 PM – 12:45 PM	DEBATE #2 The Greater Debate – 'A Pain in the RAAS' A Multidisciplinary Discussion on the Management of Radiation-Associated Angiosarcoma Moderators: <i>Jonathan C. Trent, MD, PhD & Rebecca A. Gladdy, MD, PhD, FRCSC</i> Presenters: <i>Mark A. Dickson, MD</i> <i>Elizabeth H. Baldini, MD, MPH</i> <i>Piotr Rutkowski, MD, PhD</i> <i>Andrew E. Rosenberg, MD</i>	Royal Palm Ballroom
12:45 PM – 1:45 PM	Lunch	Grand Ballroom
12:45 PM – 1:45 PM	CTOS All Committees Meeting	Addison West
1:45 PM – 2:45 PM	SESSION 13: Bone Tumors: Chemo Resistance, Mental Health and Surgical Insights Moderators: <i>Shintaro Iwata, MD; Susanne Scheipl, MD, PhD;</i> <i>AeRang Kim, MD, PhD; Santiago A. Lozano-Calderon, MD, PhD</i>	Royal Palm Ballroom
2:45 PM – 3:45 PM	SESSION 14: GIST Revisited: Resistance, Biology and Future Targets Moderators: <i>Emily Jonczak, MD; Jens Jakob, MD;</i> <i>Valerie Shiwen S. Yang, MD, PhD</i>	Royal Palm Ballroom
3:45 PM – 4:00 PM	Coffee Break and Posters	Grand Ballroom
4:00 PM – 5:00 PM	SESSION 15: Liposarcoma: Biology, Biomarkers and Trials Moderators: <i>Priya Chudasama, PhD; Daniela Katz, MD, MHA;</i> <i>Carolyn Nessim, MD, MSc, FRCSC, FACS</i>	Royal Palm Ballroom
5:00 PM – 5:30 PM	CTOS Business Meeting	Royal Palm Ballroom
5:30 PM	Adjourn	

See You Next Year in Seoul – November 18-21, 2026!





**Your patients with
synovial sarcoma can't wait.**

TEST FOR BIOMARKERS TODAY.

In advanced synovial sarcoma, time is critical.
That's why early biomarker testing is an important
step to help determine the treatment path forward.



StartBiomarkerTestingToday.com

US WorldMeds offers testing at
no cost for your eligible patients.



2025 SPAGN MEMBER GROUPS



Working together, making a difference.



ctos[®]

See you in Seoul



November 18-21
2026





ctos[®] |

Bringing together the
world's sarcoma specialists[®]

The Connective Tissue Oncology Society

For more information,
Please visit the CTOS website:
www.ctos.org

P.O. Box 320574 Alexandria, VA 22320
Phone: 301/502-7371 e-mail: ctos@ctos.org

Barbara Rapp, Executive Director